Product description

APO- PERINDOPRIL 2MG Tablets (Blister Packs of 30) - 2mg perindopril erbumine per tablet.

See a list of details to help identify the product

Reason the product is recalled

Some cartons of Perindopril 2mg tablets labelled with the above batch numbers may contain Perindopril 8mg tablets.

The hazards to consumers

Perindopril is a medicine used to treat high blood pressure and heart failure. A patient taking an 8mg tablet instead of a 2 mg tablet could suffer serious adverse effects such as low blood pressure, dizziness and fainting.

What consumers should do

If you have APO-Perindopril 2mg tablets from one of the above batches in your possession you should return these to your pharmacy as quickly as possible to arrange for a replacement.

If you have concerns about the use of this product you should consult your medical practitioner.

Details to help identify the product

Supplier running the recall

Apotex Pty Ltd

Identifying product features

APO-Perindopril 2mg tablets cartons marked with the following batch numbers and expiry dates are affected: Batch No. 24967 - Expiry Date: April 2013 Batch No. 24979 - Expiry Date: April 2013 Batch No. 25180 - Expiry Date: May 2013 Batch No. 25184 - Expiry Date: May 2013 The batch numbers are displayed on the end flap of the 2mg carton. ARTG number 151911

Identifying numbers

Other identifying numbers

APO-Perindopril 2mg tablets cartons marked with the following batch numbers and expiry dates are affected:

Batch No. 24967 - Expiry Date: April 2013
Batch No. 24979 - Expiry Date: April 2013
Batch No. 25180 - Expiry Date: May 2013
Batch No. 25184 - Expiry Date: May 2013

The batch numbers are displayed on the end flap of the 2mg carton.

ARTG number 151911

Where the product was sold

Nationally

Responsible regulators

Regulators are established or appointed by government. They enforce regulations and rules.

Quote PRA number 2010/12116 when contacting a regulator about this recall.

Recall and remedy questions

Contact the Therapeutic Goods Administration if you have:

  • a question about the remedy being offered to you by the business that is responsible for managing this recall, or
  • concerns about the way the business is managing this recall.